No Place Like Home: The Growing Acceptance of Subcutaneous Immune Globulin
Is SCIG well-accepted by most patients either previously treated with IVIG or just starting out on IG therapy?
FDA Approves Sandoz’s Ziextenzo as 24th Biosimilar
The U.S. Food and Drug Administration (FDA) has approved Ziextenzo (pegfilgrastim-bmez), the 24th biosimilar approval in the U.S.
A Guide to Immune Globulin Billing and Reimbursement
Reimbursement for expensive immune globulin (IG) therapies can be challenging and frustrating for providers. Here’s a guide to help ensure they are reimbursed for the cost of these medications.
Octapharma Introduces New SCIG Product and IgCares Program
Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) at the Immune Deficiency Foundation (IDF) National Conference in June.
Anti-Influenza Hyperimmune Immune Globulin Not Effective in Hospitalized Adults with Influenza Infection
A trial was conducted to assess the safety and efficacy of hIVIG (in conjunction with standard care) in adults hospitalized with laboratory-confirmed influenza A or B infection.